Article

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients

The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
American Journal of Hematology (Impact Factor: 3.48). 09/2007; 82(9):831-3. DOI: 10.1002/ajh.20961
Source: PubMed

ABSTRACT Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity. Using data from the APEX (Richardson et al., N Engl J Med 2005;352:2487-2498) study, we have assessed the relationship of changes in alkaline phosphatase (ALP) levels during bortezomib therapy with response and time to progression on this therapy. The percentage of ALP increments in responders (complete and partial response) and nonresponders was analyzed at different thresholds and time points. For all bortezomib-treated patients enrolled in the trial (N = 333), at least a 25% increase in ALP from the baseline at 6 week was the most powerful predictor of treatment response (P < 0.0001) and time to progression (206 vs. 169 days) relative to patients with less than a 25% increase in ALP (P = 0.01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth.

Download full-text

Full-text

Available from: Dixie Esseltine, Oct 01, 2014
0 Followers
 · 
124 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A method for designing more regular (more differentiable) scaling functions than the Daubechies (1992) wavelets is presented. The approach is to numerically minimize the Holder exponent (a measure of smoothness) subject to constraints on the autocorrelation sequence of the scaling filter. The “maximally smooth” wavelets which result have a Holder exponent which grows faster than that of the Daubechies orthogonal wavelets, as the filter length increases. This is achieved by relaxing some of the vanishing moment conditions
    Acoustics, Speech, and Signal Processing, 1996. ICASSP-96. Conference Proceedings., 1996 IEEE International Conference on; 06/1996
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone metabolism and turnover are strongly altered in multiple myeloma, as a consequence of the proliferation of malignant cells resembling plasmacells in the bone marrow. By both direct or indirect secretion of several molecules, and cell-to-cell interactions, multiple myeloma cells lead to severe and disabling skeletal alterations, such as osteolytic lesions, pathologic fractures, and osteoporosis. In this review, we summarize the studies concerning the soluble molecules which are supposed to have a role in this pathological process. We then consider the substances that, either in serum or urine specimens, can be dosed in the affected patients, thus giving an indirect measure of their altered bone turnover. In the last part of our review, we discuss the potential action of the new anti-myeloma drug bortezomib (Velcade(®), Janssen-Cilag), in opposing and maybe reverting, through a possible direct "proosteoblastic" effect, the deranged bone turnover which characterizes this disabling and unavoidably deathly disease.
    Clinical Cases in Mineral and Bone Metabolism 01/2008; 5(1):67-70.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bortezomib and pemetrexed are approved anticancer agents with non-overlapping mechanisms of action and toxicity. We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors. Two separate dose-escalating arms (arm A and arm B) were conducted simultaneously. Patients received pemetrexed on day 1 (D1) (500-600 mg/m2 IV) every 21 days. In arm A, bortezomib was given twice weekly (0.7-1.3 mg/m2 on D1, 4, 8, and 11). In arm B, bortezomib was given weekly (1.0-1.6 mg/m2 on D1 and 8). We treated 27 patients on four dose levels in arm A and three dose levels in arm B. Tumor types included lung (n = 16), adenoid cystic carcinoma (n = 2), prostate (n = 2), sarcoma (n = 2), breast (n = 1), thymus (n = 1), head and neck (n = 1), and gastrointestinal(n = 2). Dose-limiting toxicities were seen in arm A only; grade 3 asthenia (n = 2), grade 3 transaminitis and dehydration (n = 1). The most common grade 3/4 toxicity was neutropenia. Of 26 evaluable patients, 2 patients had partial response (1 in arm A and 1 in arm B), 13 had stable disease (7 in arm A and 6 in arm B), and 11 had progression (6 in arm A and 5 in arm B). Of the 16 patients with non-small cell lung cancer, 2 (12.5%) had partial response and 9 had stable disease, for a disease control rate of 68.8%. Recommended phase II dose for arm A is pemetrexed 500 mg/m2 and bortezomib 1.3 mg/m2 twice weekly. For arm B, the recommended dose is pemetrexed 500 mg/m2, bortezomib 1.6 mg/m2 weekly. Pemetrexed with bortezomib is feasible and tolerable at recommended single-agent doses. Based on the observed efficacy, a phase II study in non-small cell lung cancer is warranted.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 01/2008; 2(12):1112-6. DOI:10.1097/JTO.0b013e31815ba7d0 · 5.80 Impact Factor
Show more